<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485848</url>
  </required_header>
  <id_info>
    <org_study_id>ACT12601</org_study_id>
    <secondary_id>U1111-1124-2062</secondary_id>
    <nct_id>NCT01485848</nct_id>
  </id_info>
  <brief_title>EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer</brief_title>
  <acronym>ESP2011-002</acronym>
  <official_title>EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperance Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperance Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives: o Run-in Phase: Determine a dose of EP-100 at which the initial&#xD;
      benefit/risk of paclitaxel combined with EP-100 can be studied. o Randomized Phase: Compare&#xD;
      the anti-tumor effects of EP-100 combined with weekly paclitaxel versus paclitaxel alone in&#xD;
      patients with ovarian cancer. Secondary Objectives: o Randomized Phase: Quantify any&#xD;
      significant changes in the safety profile of weekly paclitaxel alone compared to the doublet&#xD;
      combination of paclitaxel with EP-100. o Determine an initial benefit/risk profile for this&#xD;
      new drug combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total duration of the study for each participant is 9 to 10 months, consisting of a 1 month&#xD;
      screening period, a 6 to 7 months treatment period, and a 30 day follow-up. All patients with&#xD;
      stable disease or who have achieved partial or complete response and for whom dosing has been&#xD;
      safe and reasonably well-tolerated may continue additional treatment cycles on the same&#xD;
      regimen. Any patient whose imaging assessment shows disease progression after receiving at&#xD;
      least two cycles of single agent weekly paclitaxel on ARM 1 may then be offered treatment&#xD;
      with the combination of EP-100 plus paclitaxel in the same dose regimen as ARM 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with dose limiting toxicities (DLTs) at different doses</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP) - Time</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival - Time</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) - Time</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response - Time</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Ovarian Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 1 hour intravenous infusion every week for 6 cycles (each cycle is 4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel + EP-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel every week plus EP-100 twice weekly by 1 hour intravenous infusion for the first 3 weeks of each 4 week cycle for 6 cycles (each cycle is 4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EP-100</intervention_name>
    <description>Pharmaceutical form:Solution Route of administration: Intravenous</description>
    <arm_group_label>Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Pharmaceutical form:Solution Route of administration: Intravenous</description>
    <arm_group_label>Paclitaxel + EP-100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adult patients with histologically confirmed epithelial ovarian carcinomas; these will&#xD;
             include primary peritoneal and fallopian tube carcinomas. Patient's tumor shown to be&#xD;
             positive for the LHRH-receptors by standardized immunocytochemistry performed at the&#xD;
             study's central laboratory.&#xD;
&#xD;
          -  Reliable cancer treatment history documenting advanced disease in patients who have&#xD;
             progressed during or recurred after treatment with a paclitaxel and/or platinum&#xD;
             regimen for advanced disease.&#xD;
&#xD;
          -  Evaluable disease based on criteria of the Gynecologic Intergroup Response Evaluation&#xD;
             Criteria in in Solid Tumors.&#xD;
&#xD;
          -  Karnofsky performance status &gt;/= 70%.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Significant cardiac disease.&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infections requiring systemic&#xD;
             therapy.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Treatment with radiation therapy or investigational therapy within 4 weeks prior to&#xD;
             Day 1. Had received chemotherapy prior to study entry equivalent to 3 to 5 half-lives&#xD;
             of that chemotherapy agent or 4 weeks prior to study entry (whichever is shorter) with&#xD;
             resolution of any side effects from that previous therapy (6 weeks for nitrosoureas or&#xD;
             Mitomycin C.)&#xD;
&#xD;
          -  Subjects with known central nervous system (CNS) metastases, either previously treated&#xD;
             or current.&#xD;
&#xD;
          -  Disease-free and off therapy for any other cancer within 5 years, except for&#xD;
             adequately treated basal cell or squamous cell skin cancer or cervical intraepithelial&#xD;
             neoplasia (CIN).&#xD;
&#xD;
          -  Had major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1. o Had&#xD;
             minor surgery (superficial incisions unlikely to obscure bleeding or infections)&#xD;
             within 2 weeks prior to Day 1.&#xD;
&#xD;
          -  Potentially life-threatening disease (hypercalcemia, spinal cord compression) whose&#xD;
             disease may progress acutely during therapy.&#xD;
&#xD;
          -  Unwilling or unable to comply with procedures required in this protocol.&#xD;
&#xD;
          -  Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.&#xD;
&#xD;
          -  Susceptibility to histamine release.&#xD;
&#xD;
          -  Chronic treatment with corticosteroids.&#xD;
&#xD;
          -  Baseline QTc exceeding 450 msec (by Bazett's formula) and/or patients receiving class&#xD;
             1A or class III antiarrythmic agents.&#xD;
&#xD;
          -  Serious nonmalignant disease.&#xD;
&#xD;
          -  Subjects who are currently receiving any other investigational agent.&#xD;
&#xD;
          -  Inadequate renal and liver functions and bone marrow reserve.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904-2011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840005</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840007</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840010</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840011</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840503</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>58715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840008</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227-1191</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840603</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840103</name>
      <address>
        <city>Mount Vernon</city>
        <state>Washington</state>
        <zip>98273</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840403</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840303</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98415-0299</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840203</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>December 2, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <last_update_submitted>June 9, 2014</last_update_submitted>
  <last_update_submitted_qc>June 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

